Novogene Co., Ltd. (SHA:688315)
China · Delayed Price · Currency is CNY 14.42
+0.23 (1.62%)
At close: Mar 6, 2026
Novogene Market Cap
Novogene has a market cap or net worth of 5.84 billion as of March 6, 2026. Its market cap has increased by 2.85% in one year.
Market Cap
5.84B
Enterprise Value
4.41B
Revenue
2.17B
Ranking
n/a
PE Ratio
33.48
Stock Price
14.42
Market Cap Chart
Since April 13, 2021, Novogene's market cap has decreased from 10.97B to 5.84B, a decrease of -46.73%. That is a compound annual growth rate of -12.07%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 5.84B | 8.58% |
| Dec 31, 2025 | 5.38B | 6.24% |
| Dec 31, 2024 | 5.06B | -47.88% |
| Dec 29, 2023 | 9.71B | -8.02% |
| Dec 30, 2022 | 10.56B | -36.10% |
| Dec 31, 2021 | 16.53B | 50.73% |
| Apr 13, 2021 | 10.97B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Lifecome Biochemistry | 6.55B |
| Beijing Konruns Pharmaceutical | 6.50B |
| Shanghai OPM Biosciences | 6.37B |
| R&G PharmaStudies | 6.30B |
| Xiangxue Pharmaceutical | 6.25B |
| GemPharmatech | 6.05B |
| Kexing Biopharm | 5.97B |
| Shouyao Holdings (Beijing) Co., LTD. | 5.86B |